Search Results - "Lurkin, I."

Absence of TERT promoter mutations in esophageal adenocarcinoma by Nistelrooij, A.M.J., Zwarthoff, E.C., Post, E., Lurkin, I., Marion, R., Kopershoek, E., Biermann, K., Wijnhoven, B.P.L., Dinjens, W.N.M.

Get full text

Absence of BRAF and HRAS mutations in eruptive Spitz naevi by Gantner, S., Wiesner, T., Cerroni, L., Lurkin, I., Zwarthoff, E.C., Landthaler, M., Hafner, C.

“…Summary Background  Eruptive Spitz naevi have been reported rarely in the literature. In solitary Spitz naevi, BRAF and HRAS mutations, as well as increased…”
Get full text

20-gene expression signature to predict lymph node positive disease at radical cystectomy for muscle-invasive bladder cancer: Not validated by Van Kessel, K, Van De Werken, H, Lurkin, I, Ziel–Van Der Made, A, Zwarthoff, E, Boormans, J

Get full text

837 Improved diagnostic urine assay to select patients for initial cystoscopy by Van Kessel, K.E.M, Beukers, W, Lurkin, I, Van Der Keur, K.A, Dyrskjot, L, Segersten, U, Ørntoft, T.F, Malats, N, Malmström, P.U, Real, F.X, Bangma, C.H, Zwarthoff, E.C

Get full text

Absence of TERT promoter mutations in esophageal adenocarcinoma: Letter to the Editor by van Nistelrooij, A.M.J., Zwarthoff, E.C., Post, E., Lurkin, I., van Marion, R., Kopershoek, E., Biermann, K., Wijnhoven, B.P.L., Dinjens, W.N.M.

Get full text

The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate by VAN RHIJN, Bas W. G, LURKIN, Irene, RADVANYI, Francois, KIRKELS, Wim J, VAN DER KWAST, Theodorus H, ZWARTHOFF, Ellen C

“…We analyzed the possible prognostic value of the recently discovered fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer. A FGFR3 mutation…”
Get full text

Absence of BRAF and HRAS mutations in eruptive Spitz naevi: Genetic analysis of eruptive Spitz naevi by Gantner, S., Wiesner, T., Cerroni, L., Lurkin, I., Zwarthoff, E.C., Landthaler, M., Hafner, C.

Get full text

Abstract P3-06-01: Hotspot mutations in PIK3CA are predictive for treatment outcome on aromatase inhibitors but not for tamoxifen by Ramirez, Ardila DE, Helmijr, JC, Lurkin, I, Look, M, Ruigrok-Ritstier, K, Simon, I, Van Laere, S, Sweep, F, Span, P, Linn, S, Foekens, J, Sleijfer, S, Berns, EMJJ, Jansen, MPHM

“…Introduction: PIK3CA is the most frequent (30%) mutated oncogene in breast cancer and may lead to an activation of the PI3K/AKT/mTOR-pathway. Cell lines…”
Get full text

Microsatellite analysis: DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma a phase II trial by VAN RHIJN, Bas W. G, LURKIN, Irene, KIRKELS, Wim J, VAN DER KWAST, Theodorus H, ZWARTHOFF, Ellen C

“…It has been shown that microsatellite analysis (MA) is able to detect bladder carcinoma in urine. Relatively small groups of patients often with high stage and…”
Get full text

39 Mutaties in PIK3CA en FGFR3 correleren met een gunstige prognose na radicale cystectomie voor het spierinvasief blaascarcinoom by Lely, F.C., Zuiverloon, T.C.M., Boormans, J.L., Abas, C., Lurkin, I., Roshani, H., Oomens, E., van der Hoeven, J., Boevé, E., Zwarthoff, E.C.

“…Samenvatting Oncogene mutaties in de PIK3CA - en FGFR3 -genen stimuleren proliferatie van tumorcellen en spelen een rol bij de pathogenese van blaastumoren. In…”
Get full text

264 - 20-gene expression signature to predict lymph node positive disease at radical cystectomy for muscle-invasive bladder cancer: Not validated by Van Kessel, K., Van De Werken, H., Lurkin, I., Ziel–Van Der Made, A., Zwarthoff, E., Boormans, J.

Get full text